Redeye reviews SynAct Pharma's Q4 report. A new European study in respiratory insufficiency was initiated in February. The ADVANCE study was fully enrolled with 246 patients, also in February; this means topline data will be available in Q2 2026, a major catalyst.
LÄS MER
